Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation

Acta Pharmaceutica

Volumn 60, Issue 2, 2010, Pages 153-163

  Bachhav, Yogeshwar ^a,b   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

anti inflammatory activity; gel; meloxicam; skin irritation; skin permeation; stability

Indexed keywords

1 METHYL 2 PYRROLIDINONE; MELOXICAM; PIROX; PIROXICAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; GEL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PH; RABBIT; RAT; SKIN IRRITATION; SKIN PERMEABILITY; TOPICAL DRUG ADMINISTRATION; VISCOSITY;

EID: 78650130732     PISSN: 13300075     EISSN: 18469558     Source Type: Journal    
DOI: 10.2478/v10007-010-0020-0     Document Type: Article

References (19)

1. S. Noble and J. A. Balfour, Meloxicam, Drugs 51 (1996) 424-430; DOI: 10.2165/00003495-199651030-00007.
2. N. M. Davies and N. M. Skjodt, Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug, Clin. Pharmacokinet. 36 (1999) 115-126; DOI: 2165/00003088-199936020-00003.
3. B. J. Gates, T. T. Nguyen, S. M. Setter and N. M. Davies, Meloxicam: a reappraisal of pharmaco-kinetics, efficacy and safety, Expert Opin. Pharmacother. 6 (2005) 2117-2140; DOI: 10.1517/14656566.6.12.2117. (Pubitemid 41600587)
4. M. R. Prausnitz, S. Mitragotri and R. Langer, Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov. 3 (2004) 115-124; DOI: 10.1038/nrd1304. (Pubitemid 38239773)
5. E. Beetge, J. D. Plessis, D. G. Muller, C. Goosen and F. J. Van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAIDs on their transdermal absorption, Int. J. Pharm. 193 (2000) 261-264; DOI: 10.1016/S0378-5173(99)00340-3. (Pubitemid 30001870)
6. P. Stei, B Kruss, J. Weigleb and V. Trach, Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration, Br. J. Rheumatol. 35 (1996) 44-50; DOI: 10.1093/rheumatology/35. suppl-1.44.
7. R. Jantharaprapap and G. Stagni, Effects of penetration enhancers on in vitro permeability of meloxicam gels, Int. J. Pharm. 343 (2007) 26-33; DOI: 10.1016/j.ijpharm.2007.04.011. (Pubitemid 47321008)
8. J. S. Chang, Y. B. Huang, S. S. Hou, R. J. Wang, P. C. Wu and Y. H. Tsai, Formulation optimiza-tion of meloxicam sodium gel using response surface methodology, Int. J. Pharm. 338 (2007) 48-54; DOI: 10.1016/j.ijpharm.2007.01. 033. (Pubitemid 46777218)
9. Y. Yuan, S. M. Li, F. K. Mo and D. F. Zhong, Investigation of microemulsion system for trans-dermal delivery of meloxicam, Int. J. Pharm. 321 (2006) 117-123; DOI: 10.1016/j.ijpharm.2006.06.021. (Pubitemid 44247427)
10. ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva 2005, Switzerland.
11. M. Joshi and V. Patravale, Nanostructured lipid carrier (NLC) based gel of celecoxib, Int. J. Pharm. 346 (2008) 124-132; DOI: 10.1016/j.ijpharm.2007.05. 060 (Pubitemid 350110507)
12. United States Pharmacopoeia 24, National Formulary 19, USP Pharmacopoeial Convention, Rock-wille (MD) 2000.
13. ICH Topic Q1 A (R2) Stability Testing of new Drug Substances and Products (2005), Interna-tional Conference on Harmonisation of Technical requirements for Registration of Pharmaceuti-cals for Human Use, Geneva, Switzerland.
14. B. J. Vermeer, Skin irritation and sensitization, J. Control. Rel. 15 (1991) 261-265; DOI: 10.1016/0168-3659(91)90117-V.
15. E. Pontiki and D. Hadjipavlou-Litina, Synthesis of phenyl-substituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors, Med. Chem. 3 (2007) 175-186; DOI: 10.2174/157340607780059512. (Pubitemid 47454882)
16. M. D. Joshi and V. B. Patravale, Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib, Drug Dev. Ind. Pharm. 32 (2006) 911-918; DOI: 10.1080/03639040600814676. (Pubitemid 44359752)
17. R. Sanghavi, R. Narazaki, S. G. Machatha and S. H. Yalkowsky, Solubility improvement of drugs using N-methyl pyrrolidone, AAPS PharmSci Tech. 9 (2008) 366-376; DOI: 10.1208/s12249-008-9050-z.
18. P. J. Lee, R. Langer and V. P. Shastri, Role of N-methyl pyrrolidone in the enhancement of aque-ous phase transdermal transport, J. Pharm. Sci. 94 (2005) 912-917; DOI: 10.1002/jps.20291. (Pubitemid 40577322)
19. A. C. Williams and B. W. Barry, Penetration enhancers, Adv. Drug Del. Rev. 56 (2004) 603-618; DOI:10.1016/j.addr.2003.10.025. (Pubitemid 38326936)